141 related articles for article (PubMed ID: 36165723)
1. Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors.
Li Y; Wu L; Tao W; Wu D; Ma F; Li N
Biomed Res Int; 2020; 2020():5658904. PubMed ID: 32596330
[TBL] [Abstract][Full Text] [Related]
2. The FGF/FGFR axis as a therapeutic target in breast cancer.
Brady N; Chuntova P; Bade LK; Schwertfeger KL
Expert Rev Endocrinol Metab; 2013 Jul; 8(4):391-402. PubMed ID: 25400686
[TBL] [Abstract][Full Text] [Related]
3. FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies.
Weeden CE; Solomon B; Asselin-Labat ML
Cell Death Discov; 2015; 1():15049. PubMed ID: 27551478
[TBL] [Abstract][Full Text] [Related]
4. FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib.
Gibson N; Larroquette M; Domblides C; Lefort F; Daste A
Eur J Cancer; 2024 May; 202():113986. PubMed ID: 38484691
[No Abstract] [Full Text] [Related]
5. Oncogene alterations in non-small cell lung cancer with
Kitai H; Ebi H
Transl Lung Cancer Res; 2024 Mar; 13(3):684-688. PubMed ID: 38601453
[No Abstract] [Full Text] [Related]
6. The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer.
Birkeland AC; Ludwig ML; Meraj TS; Brenner JC; Prince ME
Cancers (Basel); 2015 Oct; 7(4):2094-109. PubMed ID: 26506389
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas.
Knauer SK
J Oncol; 2009; 2009():349205. PubMed ID: 19794826
[TBL] [Abstract][Full Text] [Related]
8. High-resolution genomic configuration of
Hong SH; Kim TM
Transl Lung Cancer Res; 2024 Feb; 13(2):236-239. PubMed ID: 38496689
[No Abstract] [Full Text] [Related]
9. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment.
Ruan R; Li L; Li X; Huang C; Zhang Z; Zhong H; Zeng S; Shi Q; Xia Y; Zeng Q; Wen Q; Chen J; Dai X; Xiong J; Xiang X; Lei W; Deng J
Mol Cancer; 2023 Mar; 22(1):60. PubMed ID: 36966334
[TBL] [Abstract][Full Text] [Related]
10. The diverse dependence of galectin-1 and -8 on multivalency for the modulation of FGFR1 endocytosis.
Żukowska D; Chorążewska A; Ciura K; Gędaj A; Kalka M; Poźniak M; Porębska N; Opaliński Ł
Cell Commun Signal; 2024 May; 22(1):270. PubMed ID: 38750548
[TBL] [Abstract][Full Text] [Related]
11. Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome.
Broghammer F; Korovina I; Gouda M; Celotti M; van Es J; Lange I; Brunner C; Mircetic J; Coppes RP; Gires O; Dahl A; Seifert M; Cordes N
Mol Cancer; 2024 Feb; 23(1):39. PubMed ID: 38378518
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Kasi PM; Lee JK; Pasquina LW; Decker B; Vanden Borre P; Pavlick DC; Allen JM; Parachoniak C; Quintanilha JCF; Graf RP; Schrock AB; Oxnard GR; Lovly CM; Tukachinsky H; Subbiah V
Clin Cancer Res; 2024 Feb; 30(4):836-848. PubMed ID: 38060240
[TBL] [Abstract][Full Text] [Related]
13. FGFR1/2/3-rearranged carcinoma of the head and neck: expanded histological spectrum crossing path with high-risk HPV in the sinonasal tract.
Chu YH; Mullaney K; DiNapoli SE; Cohen MA; Xu B; Ghossein R; Katabi N; Dogan S
Histopathology; 2024 Mar; 84(4):589-600. PubMed ID: 38010295
[TBL] [Abstract][Full Text] [Related]
14. Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.
Wang Z; Muthusamy V; Petrylak DP; Anderson KS
NPJ Precis Oncol; 2023 Jul; 7(1):70. PubMed ID: 37479885
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial.
Kim KH; Lim SM; Ahn HK; Lee YG; Lee KW; Ahn MJ; Keam B; Kim HR; Lee HW; An HJ; Kim JS
Cancer Res Treat; 2024 Jan; 56(1):37-47. PubMed ID: 37475136
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.
Wang Z; Anderson KS
Cancer J; 2022 Sep-Oct 01; 28(5):354-362. PubMed ID: 36165723
[TBL] [Abstract][Full Text] [Related]
17. [FGFR-targeted therapy in head and neck carcinomas].
Dietrich D
HNO; 2021 Mar; 69(3):172-184. PubMed ID: 32519203
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
